Gilead Sciences and CGI Pharmaceuticals, Inc. have entered into a definitive agreement under which Gilead will acquire CGI for as much as $120 million—the majority as an upfront payment and the rest based on clinical development progress. CGI will continue operations in Branford as a wholly-owned subsidiary of Gilead. The deal is expected to close in 3Q10. CGI has generated a library of small molecule kinase inhibitors. Its lead preclinical compound targets spleen tyrosine kinase (Syk), which...